Clinical Trial

Managed Access Programs for TQJ230, Pelacarsen

Available
View on ClinicalTrials.gov →
Summary
The purpose of this registration is to list Managed Access Programs (MAPs) related to TQJ230, pelacarsen
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-22.
Trial Details
NCT Number NCT07000695
Lead Sponsor Novartis Pharmaceuticals
Conditions Atherosclerotic Cardiovascular Disease, ASCVD
Updated on ClinicalTrials.gov 2026-06-18